<!doctype html>
<html>
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width">
<title></title>
<link rel="stylesheet" href="css/style.css">
</head>

<body>

<header>
  <div class="l"><a href="javascript:history.back();"><span>left</span></a></div>
  <p class="title"><a href="index.html">社外秘 研修資料</a></p>
  <div class="r"><a href="377.html"><span>right</span></a></div>
</header>

<div class="wrap">
  <section>
    <h1 class="tit">アクテムラはコレステロールを上昇させる作用があるものの、心イベント発症はエンブレルと有意差がなかった（ ENTRACTE Trial ）</h1>

    <ul class="circle_n">
    	<li><span>・</span>DMARDs効果不十分なRA患者にTCZ8㎎/㎏/4週かETN50㎎/週を投与し主な心イベントの発症率を比較する（Phase4 Study）</li>
    	<li><span>・</span>CVD歴の無い50歳以上のRA患者3000名以上5年フォロー</li>
    </ul>
  </section>


  <section>
    <div class="table">
      <h3 class="tit">TCZとETNの主要エンドポイントのハザード比</h3>
      <ul class="circle_n">
        <li><span>※</span>MACE：心血管死・非致死性心筋梗塞・非致死性脳梗塞</li>
      </ul>
      <div class="sc">
        <table class="style1">
          <tr>
            <td rowspan="3">&nbsp; </td>
            <td rowspan="2" width="15%"><font size="1">Etanercept<br> N =1542 </font></td>
            <td rowspan="2" width="15%"><font size="1">Tocilizumab <br>N =1538 </font></td>
            <td colspan="2" width="30%"><font size="1">Tocilizumab <br>vs Etanercept </font></td>
          </tr>
          <tr>
            <td width="15%">&nbsp;</td>
            <td  width="15%" class="lbd_red rbd_red tbd_red"><span class="red"><font size="1">いずれも<br>有意差なし</font></span></td>
          </tr>
          <tr>
            <td><font size="1">&nbsp;First Events, n </font></td>
            <td><font size="1">First Events, n </font></td>
            <td><font size="1">HRa </font></td>
            <td class="lbd_red rbd_red"><font size="1">95% CI </font></td>
          </tr>
          <tr>
            <td><font size="1">MACE-ITT population </font></td>
            <td>78</td>
            <td>83</td>
            <td>1.05</td>
            <td class="lbd_red rbd_red">0.77, <br>1.43 </td>
          </tr>
          <tr>
            <td><font size="1">MACE-OT population </font></td>
            <td>52</td>
            <td>57</td>
            <td>1.11</td>
            <td class="lbd_red rbd_red">0.76, <br>1.62 </td>
          </tr>
          <tr>
            <td><font size="1">CVD death </font></td>
            <td>35</td>
            <td>36</td>
            <td>1.03</td>
            <td class="lbd_red rbd_red">0.64, <br>1.63 </td>
          </tr>
          <tr>
            <td><font size="1">Nonfatal MI </font></td>
            <td>31</td>
            <td>28</td>
            <td>0.89</td>
            <td class="lbd_red rbd_red">0.54, <br>1.49 </td>
          </tr>
          <tr>
            <td><font size="1">Nonfatal stroke </font></td>
            <td>15</td>
            <td>24</td>
            <td>1.53</td>
            <td class="lbd_red rbd_red">0.80, <br>2.92 </td>
          </tr>
          <tr>
            <td><font size="1">All-cause mortality </font></td>
            <td>64</td>
            <td>64</td>
            <td>0.99</td>
            <td class="lbd_red rbd_red">0.70, <br>1.41 </td>
          </tr>
          <tr>
            <td><font size="1">Expanded composite <br>end pointb </font></td>
            <td>84</td>
            <td>84</td>
            <td>0.99</td>
            <td class="lbd_red rbd_red">0.73, <br>1.34 </td>
          </tr>
          <tr>
            <td><font size="1">Hospitalized for HF </font></td>
            <td>8</td>
            <td>12</td>
            <td>1.5</td>
            <td class="lbd_red rbd_red">0.61, <br>3.67 </td>
          </tr>
          <tr>
            <td><font size="1">MACE + hospitalized for HF </font></td>
            <td>85</td>
            <td>90</td>
            <td>1.05</td>
            <td class="lbd_red rbd_red">0.78, <br>1.41 </td>
          </tr>
          <tr>
            <td><font size="1">Fatal + nonfatal MI </font></td>
            <td>32</td>
            <td>29</td>
            <td>0.9</td>
            <td class="lbd_red rbd_red">0.54, <br>1.48 </td>
          </tr>
          <tr>
            <td><font size="1">Fatal + nonfatal stroke </font></td>
            <td>16</td>
            <td>26</td>
            <td>1.55</td>
            <td class="lbd_red rbd_red bbd_red">0.83, <br>2</td>
          </tr>
        </table>
      </div>
    </div>

  </section>

  <section>
   <p>海外ではRA患者の死因の上位が心筋梗塞などのCVDであり、Bioがそのリスクを上げるかどうかは重要な問題である。アクテムラはコレステロールを上昇させるため、そのリスクが心配されていた</p>

  <div class="greenbox"><p>心イベント発症はアクテムラとエンブレルに有意差がないことが大規模無作為化試験で確認された
</p></div>

  </section>

   <p class="txt sml right"><a href="http://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/">Jon T. Giles, et al. ACR2016. #3L</a></p>
</div>

<footer>
  <div class="l"><a href="javascript:history.back();"><span>left</span></a></div>
  <div class="home"><a href="index.html"><span>HOME</span></a></div>
  <div class="r"><a href="377.html"><span>right</span></a></div>
  <div class="pagetop"><a href="javascript:scroll(0,0);">pagetop</a></div>
</footer>

<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.2/jquery.min.js"></script>
<script src="js/common.js"></script>
</body>
</html>
